
Overview of Biosimilars
Expert retina specialists discuss the efficacy and safety data of the ranibizumab biosimilar, SB11 [BYOOVIZ ▼ (ranibizumab)], and explore the practical implications of biosimilars in the broader real-world context.
Episodes in this series

This program is intended for health care providers in UK, Canada, and Switzerland. This program focuses on EU regulations and may differ from other jurisdictions.
In UK, Canada, and Switzerland, the SmPC and regulatory requirements may differ from those of the FDA and EMA.
UK (GB&NI) BYOOVIZ Prescribing Information
Please refer to the PI
Adverse events should be reported. Reporting forms and Information can be found at
Canada BYOOVIZ Prescribing Information
Consult the product monograph at
Visit the Web page on Adverse Reaction Reporting (
Switzerland BYOOVIZ Prescribing Information
BYOOVIZ, Dispensing Category B.
▼ This medicinal product is subject to additional monitoring. For further information see information for professionals of BYOOVIZ on
MA-holder: Samsung Bioepis CH GmbH, Lucerne
To report an adverse event, please email us at
Biogen- 223327 March 2024
Newsletter
Keep your retina practice on the forefront—subscribe for expert analysis and emerging trends in retinal disease management.